Can Insilico Medicine’s rentosertib slow FVC decline in Phase 3 IPF study?
Insilico Medicine starts Phase 3 testing of rentosertib in IPF, putting its AI-discovered TNIK inhibitor through a decisive 52-week trial.
Pharma & Biotech
Pharma & Biotech
Insilico rentosertib makes six proteomic aging clocks trend younger in IPF trial
A Nature Biotechnology analysis of 42 rentosertib-treated IPF trial participants found younger predicted biological-age profiles across six proteomic clocks, but researchers caution that the finding does not prove human aging was reversed.
Pharma & Biotech
How Insilico Medicine’s Virtual Aging Cell could bring biological time into AI drug discovery
Insilico Medicine is building an age-aware Virtual Aging Cell for drug discovery, but experimental validation will determine its real scientific value.
Pharma & Biotech
What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?
Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.
Pharma & Biotech
A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates
Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.
Pharma & Biotech
Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery
Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.
Features & Analysis
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
Pharma & Biotech
Insilico Medicine’s AI-designed anemia therapy begins Phase I testing in collaboration with TaiGen
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.